Hasil Pencarian - Chrisann Kyi

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

    Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhib... oleh Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj, William K. Oh

    Diterbitkan 2017-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy

    Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy oleh Chrisann Kyi, Claire F. Friedman, Jennifer J. Mueller, Ryma Benayed, Marc Ladanyi, Maria Arcila, Soo Ryum Yang, Martee L. Hensley, Sarah Chiang

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer

    Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer oleh Chrisann Kyi, Alexia Iasonos, Carol Aghajanian, Paul Sabbatini, Ekaterina Doubrovina, Sara Kravetz, David Spriggs, Richard J O'Reilly, Roisin E O’Cearbhaill

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

    Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial oleh Bin Li, Jun Li, Tian Chen, Uwe M Martens, Lazar Vujanovic, Rom Leidner, Robert L Ferris, William Sharfman, Chrisann Kyi, Suzanne L Topalian, Janis M Taube, Christine H Chung, William C Spanos, Anthony Gonçalves, Lot A Devriese, Helene Gauthier, Simon I Chiosea, Julie E Stein, Adam Barrows

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Pattern of disease and response to pembrolizumab in recurrent cervical cancer

    Pattern of disease and response to pembrolizumab in recurrent cervical cancer oleh Kathryn M. Miller, Olga T. Filippova, Sara A. Hayes, Nadeem R. Abu-Rustum, Carol Aghajanian, Vance Broach, Lora H. Ellenson, Pier Selenica, Elizabeth L. Jewell, Chrisann Kyi, Yuliya Lakhman, Jennifer J. Mueller, Roisin E. O'Cearbhaill, Kay J. Park, Yukio Sonoda, Dmitriy Zamarin, Britta Weigelt, Mario M. Leitao, Jr, Claire F. Friedman

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

    A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies oleh Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud

    Diterbitkan 2024-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies oleh Tian Zhang, Filippo de Braud, Taito Esaki, Wallace Akerley, Chrisann Kyi, Richard D Carvajal, Daniel Gusenleitner, Patrick Schöffski, Miguel Martin, David S Hong, Amy Prawira, Jürgen Krauß, Nidhi Patel, Rina Hui, Andrew Weickhardt, Niladri Roy Chowdhury, Daniel S W Tan, María Ochoa-de-Olza, John Sarantopoulos, Ross A Soo, Michela Maur, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Catherine A Sabatos-Peyton, Radha Ramesh, Tiancen Hu, Ana Carion, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: